OncoMatch/Clinical Trials/NCT06401824
Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases
Is NCT06401824 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab for nsclc stage iv.
Treatment: Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab — This study will evaluate whether the combination of sacituzumab govitecan (SG) and bevacizumab will result in shrinkage of brain metastases from patients with non-squamous non-small cell lung cancer (NSCLC), with disease progression on chemotherapy and immunotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage IV
Metastatic disease required
Pathology proven metastatic non-squamous NSCLC
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: immunotherapy
progression on immunotherapy and/or platinum-doublet chemotherapy (concurrent or sequential, in any order)
Must have received: platinum-based chemotherapy
progression on immunotherapy and/or platinum-doublet chemotherapy (concurrent or sequential, in any order)
Must have received: targeted therapy
progression on targeted therapy and platinum-doublet chemotherapy
Cannot have received: TROP2 inhibitor
Previous treatment with TROP2 inhibitor
Cannot have received: angiogenesis inhibitor
Previous treatment with...angiogenesis inhibitor
Cannot have received: anticancer biologic agent (antibody-drug conjugate, immune checkpoint inhibitor)
Exception: within 4 weeks prior to enrolment
prior anticancer biologic agent (ADC, ICI) within 4 weeks prior to enrolment
Cannot have received: chemotherapy
Exception: within 2 weeks prior to enrolment and have not recovered (ie, ≥ Grade 2 is considered not recovered) from AEs at the time of study entry
prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to enrolment and have not recovered (ie, ≥ Grade 2 is considered not recovered) from AEs at the time of study entry
Cannot have received: targeted small molecule therapy
Exception: within 2 weeks prior to enrolment and have not recovered (ie, ≥ Grade 2 is considered not recovered) from AEs at the time of study entry
prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to enrolment and have not recovered (ie, ≥ Grade 2 is considered not recovered) from AEs at the time of study entry
Cannot have received: radiation therapy
Exception: within 2 weeks prior to enrolment and have not recovered (ie, ≥ Grade 2 is considered not recovered) from AEs at the time of study entry
prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to enrolment and have not recovered (ie, ≥ Grade 2 is considered not recovered) from AEs at the time of study entry
Lab requirements
Blood counts
ANC ≥ 1.5 x 10^9/L (without growth factor support); Platelets ≥ 100 x 10^9/L (without growth factor support); Hemoglobin ≥ 6 mmol/l (= 9 g/dl) (7 days without transfusions or growth factor support)
Kidney function
Creatinine clearance ≥ 30 mL/min by Cockcroft-Gault or 24-hour urine
Liver function
AST ≤ 2.5 x ULN, or ≤ 5 × ULN if known liver metastases; ALT ≤ 2.5 x ULN, or ≤ 5 × ULN if known liver metastases; Total bilirubin ≤ 1.5 ULN; Serum albumin > 3 g/dL
Adequate organ function including the following laboratory values at the screening visit: ANC ≥ 1.5 x 10^9/L (without growth factor support), Platelets ≥ 100 x 10^9/L (without growth factor support), Hemoglobin (Hb) ≥ 6 mmol/l (= 9 g/dl) (7 days without transfusions or growth factor support), AST ≤ 2.5 x ULN, or ≤ 5 × ULN if known liver metastases, ALT ≤ 2.5 x ULN, or ≤ 5 × ULN if known liver metastases, Serum albumin > 3 g/dL, Total bilirubin ≤ 1.5 ULN, Creatinine clearance ≥ 30 mL/min by calculation using Cockcroft-Gault formula or based on 24-hour urine sample assessment.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06401824 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior TROP2 inhibitor, angiogenesis inhibitor, anticancer biologic agent disqualifies patients from enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages